Skip to main navigation
logo
  • Overview
  • Shareholder Information
    • Stock Quote & Chart
    • Financial Filings
    • Shareholder Structure
    • Shareholder Structure (NL)
    • Prospectus
    • Prospectus (NL)
    • Shareholder Meetings
    • Analyst Coverage
    • Transparency Notifications
    • Conversion Table
    • Conversion Table (NL)
  • Events & Presentations
  • News
  • Corporate Governance
    • Governance Overview
    • Governance Overview (NL)
    • Board of Directors
    • Management
  • IR Contact
    • Email Alerts
    • Contact IR

News

News

March 24, 2023
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA
PDF Version
NL
March 20, 2023
Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL
PDF Version
March 14, 2023
Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes
EN
March 9, 2023
Oxurion Receives Transparency Notification from Negma Group
EN
NL
March 2, 2023
Oxurion Receives Transparency Notification from Negma Group
EN
NL
March 2, 2023
Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding
EN
March 2, 2023
Funding Program between Oxurion and Negma Ends
EN
February 24, 2023
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
EN
NL
February 24, 2023
Oxurion Receives Transparency Notifications from Negma Group
EN
NL
February 17, 2023
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
EN
NL

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 17

Section Title

  • Who We Are
  • THR-149
  • News & Events
  • Let’s Talk

Connect with Us

  • LinkedIn
  • Twitter
  • Ⓒ2023 Oxurion NV. All rights reserved.